The invention provides a combined external medicine for treating prostate diseases and a method using the same. The combined external medicine includes a pre-immune composition comprising multi-immune powder and a noble bottle tree decoction, a lesion active composition comprising the multi-immune powder and a first medical decoction prepared from a first Chinese medical composition for treating prostate diseases, and a double rib active composition comprising the multi-immune powder and a second medical decoction prepared from a second Chinese medical composition for conditioning liver and kidney. The method includes applying the pre-immune composition on skin of lesion part and skin of the left and right ribs; waiting for 5-10 minutes; applying the lesion active composition and the double rib active composition on the skin of the lesion part and skin of the left and right ribs; and airing for 10-40 minutes.

This present disclosure relates to the fields of medicine and pharmaceuticals. In particular, the invention relates to the identification of epoxytaccalonolide microtubule stabilizers for use in inhibiting cell proliferation and disrupting normal cellular microtubule processes leading to cell death. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Novel HIF inhibitors having low cytotoxicity and suitable for ophthalmologic treatment and agents for the treatment or prevention of ischemic diseases, glaucoma, optic nerve diseases, retinal degenerative diseases, retinal degenerative diseases, angiogenic retinal diseases, cancer, neurodegenerative or autoimmune diseases are provided.

The present invention is a therapeutic or prophylactic agent for ischemic disease, glaucoma, optic nerve disease, retinal degenerative disease, retinal degenerative disease, angiogenic retinal disease, cancer, neurodegenerative disease, or autoimmune disease, which comprises as an active ingredient one or more or an extract thereof selected from the group consisting of plants belonging to the genus Asian, plants belonging to the genus Swiss, plants belonging to the genus Grape, plants belonging to the genus Brassica, fish belonging to the genus Kivinago, and so on.

Novel HIF inhibitors having low cytotoxicity and suitable for ophthalmologic treatment and agents for the treatment or prevention of ischemic diseases, glaucoma, optic nerve diseases, retinal degenerative diseases, retinal degenerative diseases, angiogenic retinal diseases, cancer, neurodegenerative or autoimmune diseases are provided.

The present invention is a therapeutic or prophylactic agent for ischemic disease, glaucoma, optic nerve disease, retinal degenerative disease, retinal degenerative disease, angiogenic retinal disease, cancer, neurodegenerative disease, or autoimmune disease, which comprises as an active ingredient one or more or an extract thereof selected from the group consisting of plants belonging to the genus Asian, plants belonging to the genus Swiss, plants belonging to the genus Grape, plants belonging to the genus Brassica, fish belonging to the genus Kivinago, and so on.

A combination composition including as active components, in synergistically effective amounts of (i) a steroidal saponin of natural or synthetic origin, a pharmaceutical acceptable salt thereof or a plant extract containing steroidal saponin, and (ii) at least a first polyphenolic compound selected from the group of hydroxycinnamic acids, flavonoids, hydroxybenzoic acids, and (iii) optionally, a second polyphenolic compound, wherein the second polyphenolic compound is hydroxycinnamic acids and its use in preventing, inhibiting, retarding or treating a subject suffering from a neurodegenerative disease or condition.

A combination composition including as active components, in synergistically effective amounts of (i) a steroidal saponin of natural or synthetic origin, a pharmaceutical acceptable salt thereof or a plant extract containing steroidal saponin, and (ii) at least a first polyphenolic compound selected from the group of hydroxycinnamic acids, flavonoids, hydroxybenzoic acids, and (iii) optionally, a second polyphenolic compound, wherein the second polyphenolic compound is hydroxycinnamic acids and its use in preventing, inhibiting, retarding or treating a subject suffering from a neurodegenerative disease or condition.

The invention provides a combined external medicine for treating prostate diseases and a method using the same. The combined external medicine includes a pre-immune composition comprising multi-immune powder and a noble bottle tree decoction, a lesion active composition comprising the multi-immune powder and a first medical decoction prepared from a first Chinese medical composition for treating prostate diseases, and a double rib active composition comprising the multi-immune powder and a second medical decoction prepared from a second Chinese medical composition for conditioning liver and kidney. The method includes applying the pre-immune composition on skin of lesion part and skin of the left and right ribs; waiting for 5-10 minutes; applying the lesion active composition and the double rib active composition on the skin of the lesion part and skin of the left and right ribs; and airing for 10-40 minutes.

The invention provides a combined external medicine for treating prostate diseases and a method using the same. The combined external medicine includes a pre-immune composition comprising multi-immune powder and a noble bottle tree decoction, a lesion active composition comprising the multi-immune powder and a first medical decoction prepared from a first Chinese medical composition for treating prostate diseases, and a double rib active composition comprising the multi-immune powder and a second medical decoction prepared from a second Chinese medical composition for conditioning liver and kidney. The method includes applying the pre-immune composition on skin of lesion part and skin of the left and right ribs; waiting for 5-10 minutes; applying the lesion active composition and the double rib active composition on the skin of the lesion part and skin of the left and right ribs; and airing for 10-40 minutes.

The invention provides a combined external medicine for treating prostate diseases and a method using the same. The combined external medicine includes a pre-immune composition comprising multi-immune powder and a noble bottle tree decoction, a lesion active composition comprising the multi-immune powder and a first medical decoction prepared from a first Chinese medical composition for treating prostate diseases, and a double rib active composition comprising the multi-immune powder and a second medical decoction prepared from a second Chinese medical composition for conditioning liver and kidney. The method includes applying the pre-immune composition on skin of lesion part and skin of the left and right ribs; waiting for 5-10 minutes; applying the lesion active composition and the double rib active composition on the skin of the lesion part and skin of the left and right ribs; and airing for 10-40 minutes.

The present invention provides a traditional Chinese medicine (TCM) composition for the treatment of diabetic retinopathy, wherein the active pharmaceutical ingredients (APIs) of the said TCM composition are: Astragali Radix 10-80 parts by weight, Pseudostellariae Radix 5-30 parts by weight, Cinnamomi Ramulus 3-25 parts by weight, Angelicae Sinensis Radix 8-60 parts by weight, Notoginseng Radix ET Rhizoma 2-15 parts by weight, Dioscoreae Rhizoma 10-80 parts by weight, Salviae Miltiorrhizae Radix ET Rhizoma 10-80 parts by weight, Pheretima 2-15 parts by weight, Rehmanniae Radix 8-60 parts by weight, and Atractylodis Macrocephalae Rhizoma 8-60 parts by weight. It has been shown by clinical experiments that, the invented TCM composition has an exact efficacy in patients with macular edema and can effectively improve the patients' visual acuity and visual field and relieve ocular fundus diseases, playing an active role in alleviating macular edema.